Integra LifeSciences
IART
262 hedge funds and large institutions have $3.95B invested in Integra LifeSciences in 2019 Q2 according to their latest regulatory filings, with 41 funds opening new positions, 94 increasing their positions, 86 reducing their positions, and 35 closing their positions.
17% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 35
1% more funds holding
Funds holding: 259 → 262 (+3)
9% more repeat investments, than reductions
Existing positions increased: 94 | Existing positions reduced: 86
3% more call options, than puts
Call options by funds: $4.72M | Put options by funds: $4.6M
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% less capital invested
Capital invested by funds: $3.96B → $3.95B (-$12.1M)
0.7% less ownership
Funds ownership: 83.43% → 82.73% (-0.7%)
Top Buyers
Top Sellers
IART Hedge Fund Activity: Q2 2019 in Review
262 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Integra LifeSciences (IART) for Q2 2019, worth a combined $3.95B — down 0.31% from $3.96B a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new IART positions and 35 closed out — a net gain of 6 holders — while 94 added to existing stakes and 86 trimmed.
The largest buyer was Hood River Capital Management, adding an estimated $21.7M. The largest seller was Fidelity Investments, cutting an estimated $119M.
- 262 institutional investors held Integra LifeSciences (IART) as of Q2 2019, up from 259 in Q1 2019.
- Funds reported $3.95B of Integra LifeSciences stock for Q2 2019, down 0.31% quarter-over-quarter.
- 41 funds opened new Integra LifeSciences positions in Q2 2019 and 35 closed out, a net change of +6 holders.
- The largest Integra LifeSciences buyer in Q2 2019 was Hood River Capital Management, an estimated $21.7M added.
- The largest Integra LifeSciences seller in Q2 2019 was Fidelity Investments, an estimated $119M sold.
Based on aggregated 13F filings for Q2 2019.